期刊文献+

复方奥硝唑搽剂的制备与质量控制 被引量:6

Preparation and quality control of compound ornidazole liniment
下载PDF
导出
摘要 目的:研制复方奥硝唑搽剂并对其质量进行控制。方法:以奥硝唑和硼酸为主药制备复方搽剂,采用紫外分光光度法和中和法分别直接测定两组分含量,并对该制剂的稳定性进行考察。结果:奥硝唑、硼酸平均回收率分别为99.98%,100.29%,RSD分别为0.49%,0.97%。结论:复方奥硝唑搽剂配方合理、质控方法可行,所得制剂性质稳定,符合中国药典2005年版的规定,可满足临床用药要求。 Objective: To study the preparotion and quality control of compound ornidazole liniment. Methods:Prepared compound liniments with ornidazole and boric acid as principle agents. The contents of these two groups were measured respectively, by UV spectrophotometry and neutralization method. Then the stability of it was examined. Results: The average recoveries of ornidazole and boric were 99. 98% and 100. 29% with the RSD of 0. 49% , 0. 97%. Conclusion :The compound ornidazole liniment formula was reasonable ; the quality control method was viable ; the outcoming liniment was stable, and in line with the 2005 version of Chinese Pharmacopoeia. It could meet the clinical requirment.
出处 《药学实践杂志》 CAS 2008年第3期203-205,共3页 Journal of Pharmaceutical Practice
关键词 奥硝唑 硼酸 搽剂 制备 质量控制 puerarin Microemulsion
  • 相关文献

参考文献7

  • 1WS1-(X-445).国家药品标准[S]47册.国家食品药品监督管理局,2003.43.
  • 2中国药典2005年版.二部[S].附录,2005:22.
  • 3中国医院制剂规范(西药制剂),第2版.北京:中国医药科技出版社,1995:85.
  • 4余翠琴,管红芳.寻常痤疮的合理药物治疗[J].中国药师,2002,5(10):625-626. 被引量:6
  • 5田怀平,王美纳.奥硝唑的药理作用及临床应用[J].中国药房,2003,14(1):50-52. 被引量:91
  • 6中国人民解放军医疗机构制剂规范[M].北京:人民卫生出版社,2007:115.
  • 7马建文,韩永平,沈克福.现代药品检验学[M].北京:人民军医出版社,1994:453.

二级参考文献20

  • 1[1]Billow JA. The Handbood of Nonprescription Drugs[M]. 12th ed. Washington.DC: American Pharmaceutical Association. 2000. 701-714
  • 2[2]Koh-Knox CP, Scott SA, Popovich NG. Therapy and topical treatment of acne vulgaris[J]. U.S. Pharmacist, 1997, 22(4): 35-44
  • 3[3]Landow K. Dispelling myths about acne[J]. Postgrad Med. 1997,102(2):94-112
  • 4[4]Thiboutot D. New treatment and therapeutic strategies for acne[J]. Arch Fam Med. 2000, 9(2): 179-187
  • 5[5]Wood A. Therapy for acne vulgaris[J]. N Eng J Mead, 1997, 336(16): 1156-1162
  • 6[1]Lamp KC, Freeman CD, Klutman NE, et al.Pharmaco- kinetics and pharmacodynamics of the nitroimidazole antimicrobials[J].Clin Pharmacokinet,1999,36(5): 353.
  • 7[2]Munoz E, Castella J, Gutierrez JF.In vivo and in vitro sensitivity of Trichomonas gallinae to some nitroimidazole drugs[J].Vet Parasitol,1998,78(4): 239.
  • 8[3]Erenmemisoglu A, Tekol Y, Aydin N.Prophylactic effect of ornidazole on experimental tetanus in mice[J].Drugs Exp Clin Res, 1995,21(2): 59.
  • 9[4]Cedillo- Rivera R, Munoz O.In- vitro susceptibility of Giardia lamblia to albendazole, mebendazole and other chemotherapeutic agents[J].J Med Microbiol, 1992,37(3):221.
  • 10[5]Okkan S, Atkovar G, Sahinler I,et al.A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: long term results[J].Br J Cancer Suppl, 1996,27: 282.

共引文献95

同被引文献33

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部